a pharmacist's view on biosimilars
Published 7 years ago • 76 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:28
the role of pharmacists when introducing biosimilar monoclonal antibodies into practice
-
1:32
the regulation of biosimilars
-
1:42
advantages of using biosimilars
-
3:09
biosimilars vs. generic drugs
-
2:43
why do we need biosimilars?
-
3:46
benefits of biosimilar medicines for patients
-
1:02:10
introduction of biosimilars on the nhs
-
3:00
biosimilars: complex copycat drugs
-
3:41
physicians concerns on the use of biomsimilars
-
1:18
can biosimilars ensure access to drugs for everyone?
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
2:24
are biosimilars as efficacious as their reference drugs?
-
1:36
an insight into novel modular sirpalpha-based cars
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:18
beat aml master sub-study: enasidenib and response-driven addition of azacitidine in idh2m aml
-
1:48
the evolving role of ai in mpns
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:21
what are biosimilars?
-
1:23
biosimilars – what they are and what you need to know.
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
5:13
phase ii trial of pembrolizumab prior to allo-sct in aml